The efficacy of chemotherapy depends on sensitivity and intrinsic or acquired drug 14 resistance of cancer cells. The n-3 long chain polyunsaturated fatty acids (n-3 LCPUFAs) are 
Introduction

29
Epidemiological studies highlight the association between long chain n-3 polyunsaturated fatty 30 acids (n-3 LCPUFAs) and reduction of different tumours such as breast [1] , colon [2] , prostate [3] , 31 liver [4] and pancreas [5] , suggesting a sensitizing n-3 LCPUFA effect. Moreover, the n-3 PUFAs 32 improve the efficacy of chemotherapy and radiation against cancer. For example, the efficacy of 33 doxorubin [6] , epirubicin [7] , 5-fluorouracil [8] , mitomycin C [9] , arabinosylcytosine [10] , 34 tamoxifen [11] , and irinotecan/CPT-11 [12] , and of radiation therapy [13] has been shown to be 35 enhanced by n-3 PUFA association. 36 reduces the resistance from 11 to 4 in the cisplatin resistant cell lines. The authors suggested that the 97 modulation of DHA incorporation could be the result of an increase of cisplatin content, which can 98 determine an enhancement of DHA platinization and adduct formation. 99 100 3. Mechanisms proposed for chemosensitizing effects of n-3 LCPUFAs. 101 The specific mechanisms involved in n-3 LCPUFAs chemosensitizing effects are not fully 102 understood, but nowadays, it is widely accepted that there are a complex network of mechanisms, 103 including alteration in gene expression [28] , modulation of cellular proliferation [29] and 104 differentiation [30] , induction of apoptosis [31] , increase in drug transport across the cell 105 membrane, generation of reactive oxygen species (ROS), and lipid peroxidation ( Figure 1 ). For 106 example, lipid peroxidation is the major mechanism exerted by doxorubicin cytotoxicity, mainly 107 correlated to the topoisomerase II inhibition and to the ROS production [32] . Moreover, the 108 cardiotoxicity caused by anthracyclines could be mediated through ROS produced during their 109 metabolism. Since DHA, with its 6 double bonds, is inclined to peroxidation, the increase of 110 membrane unsaturation index produced by DHA incorporation would enhance the ROS content 111 generated from doxorubicin metabolism [33] . This hypothesis is sustained by in vivo and in vitro 112 studies that highlight the correlation between DHA supplementation and oxidative stress resulting 113 from a higher peroxidation.
114
In this context, Vibet et al. [34] demonstrated that sensitization of breast cancer MDA-MB-231 115 cells to doxorubicin by DHA is related to a marked decrease in glutathione peroxidase (GPx), a 116 major antioxidant enzyme that uses glutathione as a reductive agent. In particular, the decrease of 117 GPx1 activity in MDA-MB-231 cells was linked to a decreased protein level but not to a decreased 118 mRNA, suggesting a DHA effect at post-transcriptional events. One hypothesis is that GPx might 119 be damaged by lipid peroxidation products produced by DHA feeding in breast cancer cells treated 120 with doxorubicin. These products lead a loss of GPx activity, probably by a modification of the 121 selenocysteine residue at the active site of the enzyme [35] . Finally, the inactivated enzyme is 122 degraded by proteases. In the same study, GPx1 activity decreased also in rat tumours after 123 supplementation with EPA/DHA or DHA alone and this reduction was associated to an increase of 124 chemosensitivity to anthracyclines.
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The most important biological function of n-3 LCPUFAs is to be precursors of bioactive lipid linolenic acid (DGLA, C20:3, n-6), arachidonic acid (AA, C20:4, n-6), EPA (C20:5, n-3) and DHA (C22:6, n-3) from sn-2 position of phospholipids. These fatty acids become substrates for 131 eicosanoid biosynthesis, depending on the cyclooxygenase (COX), lipoxygenase (LOX) or 132 cytochrome P450 monoxygenase (CYP) activities. High levels of omega-6 derived prostaglandins
133
(PG) and/or high level of cyclooxigenase 2 (COX2) are linked to many human cancer, including 134 breast, cervix, lung, skin, colon and prostate [36, 37] , so that the COX2 inhibitors, such as celecoxib, 135 indomethacin, aspirin, and piroxicam, may be used to reduce carcinogenesis. A novel approach 136 combining these drugs at low concentrations with dietary elements has been suggested to improve 137 their effects and decrease side effects. Negi K. et al. [38] showed that a combination of celecoxib 138 and n-3 PUFAs is more effective in the treatment of experimental mammary carcinogenesis, and 139 this effect can be attributed to the modification of redox signalling, with decreased c-myc, p53 140 expression, apoptosis, and proliferation. In addition, Reddy BS et al. [39] showed that low-dose 141 level of celecoxib in association with a diet containing 10% mixed lipids and 10% fish oil 142 determined a significant inhibition of COX-2 activity and expression, and colon cancer incidence 143 compared with low dose of celecoxib in a Western-style diet high in mixed lipids, including 144 saturated fats of animal origin as well as n-6 PUFAs.
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Moreover, it has been shown that the carcinogenesis inhibition induced by n-3 PUFAs is also 146 mediated through the activation of retinoid X receptors (RXR) and peroxisome proliferator 147 activated receptor (PPAR) [40] . In fact, Narayanan et al. [41] suggested that combination of DHA Recently, the new therapeutical targets in cancer treatment are increasingly specific membrane 169 proteins whose activity is modulated by changes in membrane environment. This novel approach, 170 defined "membrane lipid therapy" [46] , is based on the hypothesis that the use specific lipids might 171 alter cancer membrane composition and structure, dismantling lipid raft architecture, with 172 consequences on localization and activity of tumour crucial membrane-associated proteins, and then modulating specific cell functions [48] . 
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Our researches have demonstrated that n-3 LCPUFA incorporation into cell membrane 204 phospholipids may alter membrane fluidity, modulate cell signalling [44, 55] , and enhance the ROS 205 production and lipid peroxidation [34] . The PUFA-enriched membranes are thinner and have a 206 major fluidity compared to saturated membrane. Moreover, n-3 and n-6 PUFAs display significant 207 differences related to their different saturated chain length, longer in n-6 PUFAs [56, 57] . PUFAs, especially DHA, are incorporated in breast cancer membranes with different specificity for 211 each PL moiety: the enrichment is significant, especially in PE, PI and PC [44] . Biochemical and 212 biophysical approaches have confirmed that DHA incorporation causes morpho-dimensional 213 changes in plasma membrane, in particular in detergent resistant domains or lipid rafts [55, 58] .
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Lipid rafts are dynamic structures characterized by a relative rigidity and reduced fluidity compared 215 with the surrounding plasma membrane, and may rapidly assemble and disassemble, leading to a 216 dynamic segregation of proteins [59] . In fact, they are enriched in cholesterol and sphingo-and proteins, and modulate cellular events [62] .
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In conclusion, n-3 LCPUFAs might dismantle lipid raft structure and thereby protein lateral Furthermore, the specificity of PUFA incorporation for the PL moiety might be relevant to the 242 PUFA metabolite synthesis (prostaglandins, prostacyclins, leukotrienes, resolvines and protectines) 243 and signal transduction activation.
244
The impact of n-3 PUFAs, especially DHA, on membrane organization affect anticancer drug 245 uptake not only increasing sensitization of cancer cells but also modulating chemoresistance. 
268
Since they are well incorporated in plasma membrane phospholipids and in particular in lipid rafts, 269 this was one of the first mechanism investigated and was correlated with the increased ratio 270 between drug uptake and efflux exerted by n-3 LCPUFAs [23] . Interestingly, n-3 LCPUFAs often 271 changed the lipid compositions more in chemoresistant cells than in chemosensitive cells [21] , 272 likely as a consequence of the different membrane composition that characterizes these two cell 273 populations [69] . An increased incorporation of saturated FAs due to the de novo lipogenesis has 274 been associated with an increased resistance to doxorubicin [53] ; opposite effects should be DHA-treated cells was due to their reduced efflux.
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As noted above, several ABC transporters mediating MDR are highly sensitive to the changes in 288 lipid plasma membrane. Pgp activity for instance is activated by saturated fatty acid (SFA)-rich 289 environment and is inhibited by increased levels of MUFAs and PUFAs in plasma membrane [73] .
290
The depletion of SFAs from drug resistant cell membranes also decreased the amount of Pgp in 291 lipid-rafts compartment [73] , where the protein is abundant and active [74, 75] . We recently reported 292 that DHA and EPA were highly incorporated in the lipid rafts of MDR colon cancer cells [66] : by 293 doing so, they reduced the amount of total membrane-and lipid rafts-associated Pgp and MRP1
294
(another ABC transporter enriched in rafts [76] ), restoring the chemosensitivity to doxorubicin and 295 irinotecan. These MDR-reversing effects were peculiar of n3 FAs, but not of the n6 arachidonic 296 acid (AA): n3 FAs are indeed highly flexible structures and can produce a greater disassembly of 297 the ordered lipid rafts structure, which impairs the activity of many lipid raft-associated proteins.
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Not all the ABC transporters contained in lipid rafts, however, are inhibited by n-3 LCPUFAs: lipid rafts-associated BCRP, for instance, was increased in DHA-treated cells [66] . BCRP has a less 300 hydrophobic structure than Pgp and MRP1 [64] ; in this case, the enrichment of n-3 LCPUFAs may 301 favour the retention of BCRP in rafts compartment instead of promoting its shift in non-rafts 302 fractions. According to these data, n-3 LCPUFAs should be considered able to reverse the Since each drug can be effluxed by more than one ABC transporter [64] and resistant tumour cells 308 often express more than one transporter, this consideration freezes the enthusiasms of using n-3
309
LCPUFAs as a panacea for MDR tumours.
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Besides SFAs, cholesterol is a second component abundant in lipid rafts. Of note, it is higher in the 311 plasma membrane of chemoresistant cells than of chemosenitive cells [66, 77] . Pgp activity is 312 strictly dependent on membrane cholesterol: cholesterol depletion induces the shift of Pgp from 313 lipid rafts to non-lipid rafts compartment [78, 79] and reduces its efflux activity [77] . DHA and 314 EPA, which were well incorporated in lipid rafts, displaced cholesterol from the raft fractions of 315 MDR colon cancer cells [66] : in agreement with other experimental observations [78, 79] , this event 316 displaced Pgp from lipid rafts and lowered its activity [66] . MDR cells have a basally higher rate of resistance to the Pgp substrates doxorubicin and irinotecan [66] (Figure 4 ).
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The impact of DHA and EPA on the endogenous cholesterol synthesis, however, is rather variable PUFAs in these cells [84] , leading to hypothesize that the changes in the activity or distribution of 337 Pgp, more than in the expression of the protein, are the main responsible for chemosensitization.
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Indeed, a side-effect of PUFAs in colon cancer cells is the increased expression of the transcription 339 factors CAR and PXR [84] , which are Pgp inducers [85] : this side-effect may attenuate the down-340 regulation of Pgp. On the other hand, PUFAs reduce the activity of NF-kB, which also induces Pgp 341 [86] , adding an additional mechanism that may contribute to decrease Pgp expression [87] . The doxorubicin and cisplatin, and is associated to the MDR phenotype [90] . Interestingly, DHA has 357 been reported to decrease the activity of GPx and to sensitize MDA-MB-231 breast cancer cells to 358 doxorubicin cytotoxicity [34] . Also this effect, however, was not generalized, since GPx was 359 unaffected by DHA in other breast cancer cell lines like MCF7 [34] and it was increased, together 360 with superoxide dismutase, catalase and GST-π, in non small cell lung cancer A549 cells [91] . The From the data analyzed above, it seems clear that more than acting as general MDR reversing the former and activated the latter, they were particularly suitable in restoring gemcitabine 373 cytotoxicity in this model [93] .
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The effects of n-3 PUFAs on specific tumour subpopulations and/or on tumour stromal cells may these effects produced a significant reduction of tumour growth [96] .
399
Although contrasting in mechanisms, these studies suggest that n-3 PUFAs share the properties of 400 reversing drug resistance in vivo, by targeting both tumor cells and microenvironment.
n-3 LCPUFAs as revertants of multidrug resistance: preclinical and clinical studies 403
Curiously, several studies demonstrated the chemosensitizing efficacy of PUFAs in pre-clinical 404 models before that in vitro studies investigated the molecular mechanisms of such 405 chemosensitization. Despite the differences in the amount, type and proportion of n-3 and n-6
406
PUFAs, all the in vivo studies reported that the dietary supplementation with n-3 PUFAs improved 407 the efficacy of chemotherapy in solid and hematologic xenograft tumors [6, 10, 12, 18, 96, 97] , and in 408 endogenous tumours [94, 95] . Dogs fed with menhaden fish oil and arginine before and after 409 remission of stage III lymphoblastic lymphoma also showed prolonged disease free interval and 410 prolonged overall survival compared with animals fed with a standard diet [98] .
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When given separately and not in a mixture like fish oil, the effects of n-3 PUFAs are however a bit nor EPA increased the antitumor efficacy of gemcitabine in mice bearing colon cancers [99] .
415
Compared with the supplementation with a single n-3 PUFA, the supplementation with a mixture and activity [66] : these and other metabolic differences, which are targeted by n-3 PUFAs, may 445 amplify PUFA effects on drug resistant tumours.
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Moving to clinical settings, a first study reporting a direct correlation between the response to 447 chemotherapy and the level of n-3 LCPUFAs, in particular DHA, in adipose breast tissue [103] , effects [105] . Since the fish oil supplements used in the study included 2.2 g EPA and 240-500 mg 458 DHA, the therapeutic benefit was likely attributable to these two PUFAs. The adequate intake of n- second field of investigation that is actually unexplored.
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A third issue poorly known is represented by the inter-individual differences in PUFA absorption,
533
by the genetic polymorphisms in the enzymes involved in FA uptake, transport and metabolism, by 
